BIO-TECHNE Corp
—- Market cap
- $11.30B
- Debt
- —
- Cash
- −$264.71M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $11.30B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: TECH stock price at premium vs WAT $72.08 current versus $43.30 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WAT's multiple
Implied fair value · at TECH's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
17 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 97% equity / 3% debt · EV / Revenue 12.73x · EV proxy / EBITDA proxy 39.93x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BIO-TECHNE Corp · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Waters Corporation · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe TECH can materially improve operating margin and ROIC toward WAT's levels, then consider holding; otherwise, the current valuation looks hard to justify because TECH trades at 156.7x P/E with a -77.6% P/E-implied downside and weaker profitability across key metrics.
TECH trades at 156.7x P/E versus WAT at 35.1x, and the provided P/E-implied price of $16.13 sits far below TECH's current $72.09 price. That implies a -77.6% downside and suggests the market is paying a large premium despite TECH's weaker earnings quality and returns.
Supporting Metrics